Human embryonic stem cells: A potential system for modeling infant leukemia harboring MLL-AF4 fusion gene

Drug Discovery Today: Disease Models

Volumn 4, Issue 2, 2007, Pages 53-60

  Bueno, Clara ^a   Montes, Rosa ^a   García Castro, Javier ^a   Greaves, Mel ^b   Menendez, Pablo ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MIXED LINEAGE LEUKEMIA PROTEIN; ONCOPROTEIN; PROTEIN AF4; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CARCINOGENESIS; CHILDHOOD LEUKEMIA; CHONDROSARCOMA; DISEASE MODEL; EMBRYO DEVELOPMENT; EMBRYONIC STEM CELL; EWING SARCOMA; FUSION GENE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFANT; MALIGNANT TRANSFORMATION; MYXOSARCOMA; NONHUMAN; PROGNOSIS; REVIEW; RHABDOMYOSARCOMA; TOXICITY TESTING;

EID: 40849106320     PISSN: 17406757     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmod.2007.10.004     Document Type: Review

References (47)

1. Dick J.E., and Lapidot T. Biology of normal and acute myeloid leukemia stem cells. Int. J. Hematol. 82 (2005) 389-396
2. Wang J.C., and Dick J.E. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 15 (2005) 494-501
3. Ford A.M., et al. In utero rearrangements in the trithorax-related oncogene in infant leukaemias. Nature 363 (1993) 358-360
4. Gale K.B., et al. Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proc. Natl. Acad. Sci. U S A 94 (1997) 13950-13954
5. Greaves M.F., et al. Leukemia in twins: lessons in natural history. Blood 102 (2003) 2321-2333
6. Greaves M.F., and Wiemels J. Origins of chromosome translocations in childhood leukaemia. Nat. Rev. Cancer 3 (2003) 639-649
7. Hotfilder M., et al. Leukemic stem cells in childhood high-risk ALL/t(9;22) and t(4;11) are present in primitive lymphoid-restricted CD34+. Cancer Res. 65 (2005) 1442-1449
8. Thomson J.A., et al. Embryonic stem cell lines derived from human blastocysts. Science 282 (1998) 1145-1147
9. Lensch M.W., and Daley G.Q. Scientific and clinical opportunities for modeling blood disorders with embryonic stem cells. Blood 107 (2006) 2605-2612
10. Greaves M. Pre-natal origins of childhood leukemia. Rev. Clin. Exp. Hematol. 7 (2003) 233-245
11. Rowley J.D. The role of chromosome translocations in leukemogenesis. Semin. Hematol. 36 (1999) 59-72
12. Huret J.L., et al. An atlas of chromosomes in hematological malignancies. Example: 11q23 and MLL partners. Leukemia 15 (2001) 987-989
13. Biondi A., et al. Biological and therapeutic aspects of infant leukemia. Blood 96 (2000) 24-33
14. Felix C.A. Secondary leukemias induced by topoisomerase-targeted drugs. Biochim. Biophys. Acta 1400 (1998) 233-255
15. Spector L.G., et al. Maternal diet and infant leukemia: the DNA topoisomerase II inhibitor hypothesis: a report from the children's oncology group. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 651-655
16. Rowley J.D., and Olney H.J. International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia: overview report. Genes Chromosomes Cancer 33 (2002) 331-345
17. Greaves M.F. Infant leukaemia biology, aetiology and treatment. Leukemia 10 (1996) 372-377
18. Maia A.T., et al. Protracted postnatal natural histories in childhood leukemia. Genes Chromosomes Cancer 39 (2004) 335-340
19. Taketani T., et al. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood 103 (2004) 1085-1088
20. Moorman A.V., et al. The translocations, t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3): a cytogenetic and clinical profile of 53 patients. European 11q23 Workshop participants. Leukemia 12 (1998) 805-810
21. Daser A., and Rabbitts T.H. The versatile mixed lineage leukaemia gene MLL and its many associations in leukaemogenesis. Semin Cancer Biol. 15 (2005) 175-188
22. Chen W., et al. A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy. Blood 108 (2006) 669-677
23. Metzler M., et al. A conditional model of MLL-AF4 B-cell tumourigenesis using invertor technology. Oncogene 25 (2006) 3093-3103
24. Gaussmann A., et al. Combined effects of the two reciprocal t(4;11) fusion proteins MLL.AF4 and AF4.MLL confer resistance to apoptosis, cell cycling capacity and growth transformation. Oncogene 26 (2007) 3352-3363
25. Eguchi M., et al. MLL chimeric protein activation renders cells vulnerable to chromosomal damage: an explanation for the very short latency of infant leukemia. Genes Chromosomes Cancer 45 (2006) 754-760
26. Felix C.A., et al. Topoisomerase II and the etiology of chromosomal translocations. DNA Repair (Amst) 5 (2006) 1093-1108
27. Keller G. Embryonic stem cell differentiation: emergence of a new era in biology and medicine. Genes Dev. 19 (2005) 1129-1155
28. Menendez P., et al. Human embryonic stem cells: A journey beyond cell replacement therapies. Cytotherapy 8 (2006) 530-541
29. Allegrucci C., et al. Human embryonic stem cells as a model for nutritional programming: an evaluation. Reprod. Toxicol. 20 (2005) 353-367
30. Lau C., and Rogers J.M. Embryonic and fetal programming of physiological disorders in adulthood. Birth Defects Res. C. Embryo Today 72 (2004) 300-312
31. McMillen I.C., and Robinson J.S. Developmental origins of the metabolic syndrome: prediction, plasticity, and programming. Physiol. Rev. 85 (2005) 571-633
32. Gluckman P.D., et al. The fetal, neonatal, and infant environments-the long-term consequences for disease risk. Early Hum. Dev. 81 (2005) 51-59
33. Perez-Mancera P.A., and Sanchez-Garcia I. Understanding mesenchymal cancer: the liposarcoma-associated FUS-DDIT3 fusion gene as a model. Semin. Cancer Biol. 15 (2005) 206-214
34. Janknecht R. EWS-ETS oncoproteins: the linchpins of Ewing tumors. Gene 363 (2005) 1-14
35. Korbling M., and Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter?. Blood 98 (2001) 2900-2908
36. Chadwick K., et al. Cytokines and BMP-4 promote hematopoietic differentiation of human embryonic stem cells. Blood 102 (2003) 906-915
37. Cerdan C., et al. VEGF-A165 augments erythropoietic development from human embryonic stem cells. Blood 103 (2004) 2504-2512
38. Shalaby F., et al. A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis. Cell 89 (1997) 981-990
39. Wood H.B., et al. CD34 expression patterns during early mouse development are related to modes of blood vessel formation and reveal additional sites of hematopoiesis. Blood 90 (1997) 2300-2311
40. Wang L., et al. Endothelial and hematopoietic cell fate of human embryonic stem cells originates from primitive endothelium with hemangioblastic properties. Immunity 21 (2004) 31-41
41. Wang L., et al. Hematopoietic development from human embryonic stem cell lines. Exp. Hematol. 33 (2005) 987-996
42. Menendez P., et al. Retroviral transduction of hematopoietic cells differentiated from human embryonic stem cell-derived CD45(neg)PFV hemogenic precursors. Mol. Ther. 10 (2004) 1109-1120
43. Stewart M.H., et al. Clonal isolation of hESCs reveals heterogeneity within the pluripotent stem cell compartment. Nat. Methods 3 (2006) 807-815
44. Narayan A.D., et al. Human embryonic stem cell-derived hematopoietic cells are capable of engrafting primary as well as secondary fetal sheep recipients. Blood 107 (2006) 2180-2183
45. Tian X., et al. Hematopoietic engraftment of human embryonic stem cell-derived cells is regulated by recipient innate immunity. Stem Cells 24 (2006) 1370-1380
46. Sell S. Stem cell origin of cancer and differentiation therapy. Crit. Rev. Oncol. Hematol. 51 (2004) 1-28
47. Zelent A. APL and differentiation therapy-joint international congress. IDrugs 4 (2001) 1257-1262